Navigation Links
Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
Date:11/17/2009

BUDAPEST, Hungary, Nov. 17 /PRNewswire/ -- Hungarian drug producer Biropharma and patent holders of its main product Avemar dispute the connection American BioSciences Inc. and its partner Mate Hidvegi are making between their recently introduced product AveUltra and Avemar, a dietary supplement being used in cancer treatment internationally for 11 years.

"AveUltra and Avemar are two different sets of compounds hence the qualities of Avemar can be attributed exclusively to Avemar, therefore all references of AveUltra to Avemar is scientifically unfounded, deceptive and abundantly unethical," Avemar's co-inventors state on Avemar's website (www.avemar.com).

Avemar is a wheat germ extract formula under patent protection designed to treat cancer patients. It is produced by Biropharma based on a definite-term contract with the holders of its patent. The product is distributed under the brand 'Ave' in the U.S.

Hidvegi, one of the patent holders, has teamed up with American BioSciences to start the U.S.-based production of AveUltra, a dietary supplement also based on wheat germ extract, but different from Avemar. According to their claims, AveUltra is developed from Avemar, however, no scientific or otherwise experimental data supports this assertion.

Several clinical studies investigated the various benefits associated with Avemar treatment and the results were published in prestigious peer reviewed medical journals. These publications cannot be used to support the claims of AveUltra.

The producers of AveUltra planned to announce the start of U.S.-based manufacturing of AveUltra at the Society of Integrative Oncology's 6th International Conference at the New York Academy of Medicine on Nov. 12-13.

Avemar's Hungarian producer Biropharma, three co-inventors and a patent holder of Avemar are disputing the steps and behavior of American BioSciences Inc. and Mate Hidvegi and planning to take all necessary steps to protect their rights in Hungary and in the United States.

According to Biropharma, the start of U.S. production of a product referring to Avemar is a series of violations of contractual rights that might make the Hungarian company go out of business.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Biropharma


'/>"/>
SOURCE Biropharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
3. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
6. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
7. Reportlinker Adds Cancer Vaccines: Measuring Market Potential
8. Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound
9. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... sources for advanced technology applications, announced today that Chief Executive Officer (CEO) Debbie ... SEMI is the global industry association connecting the electronics manufacturing supply ...
(Date:4/20/2017)... , April 20, 2017 For today, ... on novel drug development and clinical research aimed at treating ... Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma ... ZIOP ). You can access our complimentary research reports on ... ...
(Date:4/19/2017)... ... 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical ... in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):